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Background: Therapy for allergic rhinitis aims to control symptoms and improve the quality 
of life. The treatment of allergic rhinitis includes allergen avoidance, environmental controls, 
pharmacologic treatment, and specific immunotherapy.
Objectives: The aim of this study is to evaluate the clinical changes and the levels of interferon-γ 
(IFN-γ) and interleukin-5 (IL-5) in nasal lavage fluid from children with allergic rhinitis after 
different types of pharmacologic treatment (mometasone, montelukast, or desloratadine).
Methods: Twenty-four children aged from six to 12 years with moderate persistent allergic 
rhinitis were randomized into three groups receiving monotherapy treatment over four weeks: 
nasal corticosteroid (mometasone), leukotriene modifier (montelukast), or antihistamine 
(desloratadine). The perception of symptom improvement during the medication use was 
evaluated at the end of the treatment. Samples of nasal lavage fluid were collected before and 
after treatment for measuring IFN-γ and IL-5 cytokines by ELISA.
Results: All parents perceived an improvement in symptoms. Significant enhancement was 
seen in the mometasone group compared to those with montelukast (P = 0.01) and desloratadine 
(P = 0.02). No significant differences were found among the three groups in the levels of IL-5 
and IFN-γ in nasal fluid at baseline or after treatment. Only the group treated with mometasone 
showed a slight but significant reduction in IL-5 levels after the treatment period as compared 
with levels before the treatment (P = 0.0469).
Conclusion: The group treated with mometasone showed better improvement of clinical 
symptoms and a slight reduction in IL-5 levels in the nasal fluid. This may indirectly reflect the 
relative immunomodulatory effects of the drugs tested.
Keywords: allergic rhinitis, cytokines, IL-5, IFN-γ, nasal fluid, desloratadine, mometasone, 
montelukast, allergy
Introduction
Allergic rhinitis (AR) is currently a global public health problem and is of major 
importance due to its large increase in world prevalence, ranging from 9% to 42% in 
the general population and 30% to 40% among children and adolescents.1–3 In Brazil, 
a previous study using the International Study of Asthma and Allergies in Childhood 
(ISAAC) method found a mean rhinitis prevalence of 25.7% in children aged 6 to 
7 years, and 29.6% in adolescents aged 13 to 14 years.4 Although AR is a disease with 
low mortality, its complications such as sinusitis, Eustachian tube dysfunction, sleep 
disorders, and chronic oral breathing, in addition to its impact on asthma, have resulted 
in high financial costs.5 In the USA alone, the direct and indirect (drugs, out-patient 
clinic, school and work absence, and daily activity restriction) annual expenditure is Biologics: Targets & Therapy 2009:3 470
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estimated to be around US $1.5 to 2 billion.6 Recent data 
have indicated that worldwide costs with AR exceed US 
$5.3 billion per year.7
The management of AR includes allergen avoidance, 
pharmacotherapy, allergen immunotherapy, and more recently 
the use of immunomodulators. The goals of the treatment are 
to relieve symptoms, improve the patient functional capacity, 
and prevent complications. Classically, treatments could be 
combined using medications applied topically, systemically, or 
both. Topical drugs include intranasal corticosteroids, anticho-
linergics, antihistamines, sympathomimetics, and chromones. 
Systemic pharmacotherapy includes oral antihistamines, sym-
pathomimetics, antileukotrienes, and particularly in severe 
cases, corticosteroids. Patients who either react inadequately 
or experience some side effects of pharmacotherapies are 
often treated with allergen immunotherapy.8–10
AR is related to an enhancement of Th2 lymphocyte 
responses, showing increased levels of Th2-profile cytokines, 
such as interleukin-4 (IL-4), IL-5, and IL-13 in nasal mucosa, 
and a local eosinophilic infiltration, associated with inhibition 
of interferon-γ (IFN-γ) production. These modified responses 
promote the inflammatory process, which is responsible for 
the disease symptoms.11
Previous studies using different pharmacotherapies have 
shown improvement in the symptoms based on clinical 
scores or questionnaires on health-related quality of life 
(HRQL); and most of medications such as chromones, 
topical or oral antihistamines, nasal or oral corticosteroids, 
and leukotriene antagonists have achieved this objective.12–16 
The present study aimed to evaluate the cytokine alterations 
in nasal lavage fluid from children with AR under different 
pharmacotherapy interventions (antileukotrienes, intranasal 
corticosteroids or antihistamines) and the clinical findings in 
order to investigate the effects of the medications on cytokine 
levels in the inflammation site and if there are differences 
between the drugs.
Patients and methods
Subjects
We enrolled subjects aged 6 to 12 years with a history 
of moderate, persistent AR, requiring pharmacotherapy, 
in the Ambulatory of Pediatric Allergy and Immunology 
of the University Hospital of Universidade Federal de 
Uberlândia, Brazil. As inclusion criteria, the subjects should 
have a positive skin prick test for mite (Dermatophagoides 
pteronyssinus, Dermatophagoides farinae and/or Blomia 
tropicalis) allergen extracts (ALK-Abelló, Madrid, Spain). 
A positive skin prick test was established as a wheal 
exceeding by more than 3 mm in diameter that of the 
diluents control. The exclusion criteria were as follow: 
asthma, unless mild and intermittent; the use of intranasal, 
inhaled, or systemic corticosteroids within 30 days of the 
study; the use of concomitant medications that could affect 
the study outcome such as intranasal chromones, intranasal 
or systemic sympathomimetics, and intranasal or systemic 
antihistamines, antileukotrienes, or clinically significant 
nasal disorders such as deviated nasal septum, chronic 
rhinosinusitis, or nasal obstruction by adenoid hypertrophy; 
and a history of upper respiratory tract infection within 
28 days of the study. The study protocol and the informed 
consent from parents or legal guardians were reviewed 
and approved by the Institutional Ethics Committee of 
Universidade Federal de Uberlandia.
Study design
This was a randomized, open labeled study performed from 
June 2005 to June 2007. During the first visit, patients were 
questioned about their clinical history and use of medications, 
and when compatible, the skin prick test was performed to 
determine eligibility. A structured questionnaire concerning 
child age and gender, family and personal history of asthma 
or atopy, and clinical information was applied. By random 
draw, 24 patients were divided into three medication groups. 
Monotherapy was supplied by the researchers over four 
weeks: montelukast, 5 mg, oral route, once a day; nasal 
mometasone furoate, 50 µg, once a day; or desloratadine, 
5 mg, oral route, once a day.
Symptom evaluation
The perception of improvement during the medication use 
was evaluated by parents or legal guardians through asking 
at the end of the four-week treatment. For that evaluation, 
the parameters were as follows: excellent (very good 
improvement); good (symptom improvement, although some 
symptoms persist); regular (small symptom improvement); and 
bad (no symptom improvement or symptoms worsened).14
Nasal lavage fluid
The nasal lavage fluid was collected from each patient before 
and after the treatment as described previously.17 Briefly, 
the patient was maintained with a ±30 degree head exten-
sion and the rhinopharynx was occluded by the soft palate. 
A volume of approximately 5.5 ml of saline solution was 
instilled into each nostril and after 10 seconds the material 
was collected, by flexion of the head, into a sterile conic tube, 
which was immediately maintained in ice, homogenized by Biologics: Targets & Therapy 2009:3 471
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agitation, and centrifuged at 1000 × g for 10 minutes at 4 °C. 
The supernatant was collected and stored at –70 °C until 
subsequent analysis.
Serum eosinophils and total serum ige
Before treatment, while collection of the nasal fluid was 
being performed, blood samples were collected from each 
patient for eosinophil counts by an electronic counter (Cell 
Dyn 3.500; Abbott Diagnostic, Abbott Park, IL, USA) 
and for measurement of total serum immunoglobulin E 
(IgE) by chemiluminescence (IMMULITE 2000_Total 
IgE; Diagnostic Products Corp., Los Angeles, CA, USA). 
Both analyses were performed in the Central Laboratory of 
Clinical Analyses at the University Hospital and were used 
to compare the groups.
Measurement of cytokines  
in nasal lavage fluid
The measurement of IL-5 and IFN-γ cytokines in nasal 
lavage fluid samples was performed by ELISA according to 
manufacturer recommendation (R&D Systems, Minneapolis, 
MN, USA). The detection limits of the assays were 7.8 pg/ml 
for IL-5 and 11.7 pg/ml for IFN-γ.
Statistical analysis
Statistical analysis was performed by using GraphPad 
Prism 4.0 (GraphPad Software, Inc., San Diego, CA, 
USA). Nonparametric tests were performed: the Kruskal–
Wallis test to compare unpaired samples between the 
groups and the Wilcoxon signed-rank test for analysis of 
paired samples before and after the treatment within the 
groups. For comparison between proportions, Fisher’s exact 
test was used. Differences were considered statistically 
significant when P  0.05.
Results
From the 24 patients initially selected for the study, five 
children were excluded during the treatment due to the use of 
nonconsented medication according to the exclusion criteria 
(four children) or withdrawal from the study (one child). 
Nineteen patients completed the study, with five children 
in the montelukast group, seven in the mometasone group, 
and seven in the desloratadine group. Table 1 shows the 
demographic, clinical, and laboratory characteristics of 
patients with AR before treatment in each group. There 
were no significant differences between the analyzed groups 
with respect to age, family history of allergy and asthma, 
associated allergic diseases, total serum IgE levels, and 
eosinophil counts.
During the treatment period, all parents perceived an 
improvement in symptoms and considered the therapy 
excellent or good (Figure 1). The group treated with 
mometasone showed a significant improvement in relation to 
the montelukast group (P = 0.0101) and to the desloratadine 
group (P = 0.0210). There were no differences between the 
montelukast and the desloratadine groups (Figure 2).
Levels of IL-5 in nasal lavage fluid before and after 
treatment in each group are demonstrated in Figure 2A. 
No significant differences were found among the three groups 
at baseline and after treatment. When analyzing cytokine 
changes in each group, median IL-5 levels showed a slight 
but significant reduction after the treatment with nasal 
mometasone compared with levels before the treatment 
(P = 0.0469). There were no differences in IL-5 levels before 
and after treatment in the montelukast or desloratadine group, 
Table 1 Demographic, clinical, and laboratory features of patients with allergic rhinitis before treatment.   There are no significant difference 
among groups (AnOVA for age, Fisher’s exact test for sex and allergy history, and Kruskal–Wallis test for serum ige and eosinophils)
Treatment groups
   Montelukast  
(n = 5)
Mometasone  
(n = 7)
Desloratadine   
(n = 7)
Age (Age ± SD) 9.66 ± 2.25 8.14 ± 1.21 9.85 ± 1.46
Sex (n, %)
  Male 3 (60%) 5 (71.4%) 4 (57.1%)
  Female 2 (40%) 2 (28.6%) 3 (42.9%)
Allergy family history (n, %) 2 (40%) 4 (57.1%) 2 (28.6%)
Serum ige (Mean ± SD) 722 ± 842 1515 ± 1723 1307 ± 1032
Serum eosinophils (Mean ± SD) 397.5 ± 183.8 477.5 ± 494.5 487.7 ± 371.9
Abbreviations: AnOVA, analysis of variance; ige, immunoglobulin e; SD, standard deviation.Biologics: Targets & Therapy 2009:3 472
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although the desloratadine group showed a slight augment 
in IL-5 levels.
Levels of IFN-γ in nasal lavage fluid samples before and 
after treatment in each group are demonstrated in Figure 2B. 
The intergroup analysis did not show significant differences 
between the groups before and after treatment. Also, median 
levels of IFN-γ in nasal fluid were not significantly different 
at baseline and after treatment in each group.
The ratio between IFN-γ/IL-5 did not show differences 
among the groups before treatment, but after the treatment a 
significant difference was found between the mometasone and 
montelukast groups (P = 0.048) and between the mometasone 
and desloratadine groups (P = 0.0023) (Figure 3).
Discussion
Concerning the clinical aspects, despite the fact that patients 
of all groups in this study showed improvement in symptoms 
based on the parents’ perception, demonstrating the benefits 
of treatment, nasal mometasone was slightly superior to 
other medications, reinforcing recent data that consider nasal 
corticosteroids as gold standard in the treatment of persistent 
AR.18–20 In extended trials, the HRQL questionnaires have been 
used to analyze the clinical response to medications in AR.21,22
Regarding the cytokine changes in nasal lavage fluid, there 
are few studies on cytokine alteration in nasal fluid in patients 
with persistent AR. Most of them were performed with seasonal 
AR or after allergen challenge. The present study showed 
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Figure 1 Parents’ symptoms perception after treatment with montelukast, mometasone, or desloratadine. All parents related excellent (black bars) or good (white bars) 
improvement. 
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Figure 2 iFn-γ (A) and iL-5 (B) levels in nasal lavage fluid from patients with allergic rhinitis before (circles) and after (squares) the treatment with montelukast, mometasone, 
or desloratadine. There are no differences among groups by Kruskal–Wallis test. 
*Significant differences before and after treatment by Wilcoxon test (P  0.05).
Abbreviations: iFn, interferon; iL, interleukin.Biologics: Targets & Therapy 2009:3 473
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